=SAGE Therapeutics (SAGE) : positive trial of depression treatment

SAGE Therapeutics reports positive top-line results from phase 2 placebo-controlled trial of SAGE-217  

• SAGE-217 met primary endpoint and provided rapid, profound and durable effects through 2-week treatment period and additional 4-week follow-up
• Well-tolerated and demonstrated highly statistically significant mean reduction in the HAM-D score compared to placebo at 15 days  beginning after one dose and maintained through Week 4 with numerical superiority though Week 6
• All secondary endpoints were consistent with primary endpoints at Day 15, including remission in 64% of SAGE-217 patients versus 23% of placebo patients
• Data support further development of SAGE-217 for MDD and related disorders